Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.
OBJECTIVE
In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years.


METHODS
GLP-2, 400 micrograms, s.c.,TID, were offered, to eleven SBS patients keeping parenteral support constant. 72-hour nutritional balance studies were performed at baseline, weeks 13, 26, 52 during two years intermitted by an 8-week washout period. In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR, lungfunction, exercise test) were measured.


RESULTS
GLP-2 compliance was >93%. Three of eleven patients did not complete the study. In the remaining 8 patients, GLP-2 significantly reduced the fecal wet weight from approximately 3.0 to approximately 2.0 kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and urinary weight constant. Renal function improved. No significant changes were demonstrated in energy intake or absorption, and GLP-2 did not significantly affect mucosal morphology, body composition, bone mineral density or muscle function.


CONCLUSIONS
GLP-2 treatment reduces fecal weight by approximately 1000 g/d and enables SBS patients to maintain their intestinal fluid and electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.
Jeppesen
P B
PB
Department of Gastroenterology CA-2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. bekker@dadlnet.dk
Lund
P
P
Gottschalck
I B
IB
Nielsen
H B
HB
Holst
J J
JJ
Mortensen
J
J
Poulsen
S S
SS
Quistorff
B
B
Mortensen
P B
PB
Scand J Gastroenterol. 2002 Apr;37(4):392-8
11989828
Nutrition. 2000 Apr;16(4):272-7
10758363
Gut. 2005 Sep;54(9):1224-31
16099790
Gastroenterol Res Pract. 2009;2009:425759
19590736
Gut. 1971 Oct;12(10):773-82
4941684
Muscle Nerve. 2002 Mar;25(3):419-26
11870720
Gastroenterology. 1990 Jan;98(1):163-74
1688373
Am J Physiol. 1994 Aug;267(2 Pt 2):R408-14
7915086
Gastroenterology. 2003 Jul;125(1):136-47
12851879
Regul Pept. 2005 Jan 15;124(1-3):105-12
15544847
J Gastrointest Surg. 1998 Mar-Apr;2(2):146-50
9834410
Gastroenterology. 1993 Apr;104(4):1171-81
7681796
Exp Physiol. 1998 Sep;83(5):605-16
9793781
Exp Physiol. 2005 Jul;90(4):437-46
15802289
Am J Physiol. 1997 Dec;273(6):G1252-62
9435550
Gut. 2004 Aug;53(8):1145-50
15247183
Surg Gynecol Obstet. 1978 May;146(5):757-67
644435
Gut. 1984 Jul;25(7):784-91
6329923
Clin Chem. 1998 Nov;44(11):2281-9
9799755
Dis Colon Rectum. 1992 Mar;35(3):245-8
1740070
Regul Pept. 2002 Jul 15;107(1-3):129-35
12137975
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7911-6
8755576
J Physiol. 1987 Aug;389:557-68
3681737
Am J Physiol. 1997 Dec;273(6):R1965-71
9435650
Clin Nutr. 2006 Feb;25(1):75-81
16356596
Gastroenterology. 2001 Mar;120(4):806-15
11231933
Am Rev Respir Dis. 1969 May;99(5):696-702
5772056
Eur Respir J Suppl. 1993 Mar;16:41-52
8499053
Scand J Gastroenterol. 1998 Aug;33(8):828-32
9754730
Endocrinology. 1986 Oct;119(4):1467-75
3530719
Eur Respir J Suppl. 1993 Mar;16:5-40
8499054
Scand J Gastroenterol. 1999 Aug;34(8):818-23
10499484
Med Sci Sports Exerc. 2005 Jun;37(6):937-43
15947717
Am J Physiol. 1997 Jun;272(6 Pt 1):E1050-8
9227451
Gut. 1998 Dec;43(6):763-9
9824602
JPEN J Parenter Enteral Nutr. 1999 Sep-Oct;23(5 Suppl):S101-5
10483907
Int J Sports Med. 2003 Apr;24(3):183-9
12740736
Bone. 2007 Mar;40(3):723-9
17081815
J Clin Endocrinol Metab. 1999 Jul;84(7):2513-7
10404829